Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. [electronic resource]
Producer: 20040720Description: 632-8 p. digitalISSN:- 0954-7894
- Adolescent
- Adult
- Aged
- Androstadienes -- administration & dosage
- Anti-Asthmatic Agents -- adverse effects
- Antibodies, Anti-Idiotypic -- adverse effects
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Asthma -- drug therapy
- Bronchodilator Agents -- administration & dosage
- Child
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Fluticasone
- Humans
- Immunoglobulin E -- immunology
- Male
- Middle Aged
- Omalizumab
- Quality of Life
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.